Topical nerve growth factor prevents neurodegenerative and vascular stages of diabetic retinopathy.
diabetic retinopathy
nerve growth factor
neurodegeneration
prevention
topical treatment
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
08
2022
accepted:
29
08
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
Specific and effective preventive treatment for diabetic retinopathy (DR) is presently unavailable, mostly because the early stages of the complication have been, until recently, poorly understood. The recent demonstration that the vascular phase of DR is preceded and possibly caused by the neurodegeneration of retinal ganglion cells suggests that DR could, at least theoretically, be prevented through an early neuroprotective approach. The aims of our study were to clarify the natural history of diabetes-driven retinal neurodegeneration and to verify the possibility to prevent DR using topical nerve growth factor (NGF). The results of the study show that retinal neurodegeneration, characterized by the loss of retinal ganglion cells represents a relatively early phenomenon of diabetes (between 5 and 16 weeks of age), which tends to be self-limiting in the long run. Neurodegeneration is followed by the development of DR-related vascular dysfunctions, as confirmed by the development of acellular capillaries and the loss of retinal pericytes. Both retinal neurodegeneration and subsequent vascular dysfunction can be successfully prevented by topical NGF administration. These findings suggest that: 1) The first stage of DR consists in a self-limiting retinal neurodegeneration 2) The demonstrated effectiveness of topical NGF in the prevention of DR could be rapidly translated into clinical practice.
Identifiants
pubmed: 36172176
doi: 10.3389/fphar.2022.1015522
pii: 1015522
pmc: PMC9510636
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1015522Informations de copyright
Copyright © 2022 Zerbini, Maestroni, Leocani, Mosca, Godi, Paleari, Belvedere, Gabellini, Tirassa, Castoldi, Viganò, Galbiati, Turco, Lambiase and Rama.
Déclaration de conflit d'intérêts
AL Consultant/advisor and Licensed intellectual property Dompé Farmaceutici SpA (Milan, Italy). PR Licensed intellectual property Dompé Farmaceutici SpA (Milan, Italy). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2019 Oct 31;9(1):15778
pubmed: 31673015
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13469-74
pubmed: 19805021
Brain Res. 2007 Jan 5;1127(1):45-51
pubmed: 17113055
Diabetologia. 2018 Sep;61(9):1902-1912
pubmed: 30030554
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3860-8
pubmed: 19264888
Diabetes. 2017 Sep;66(9):2503-2510
pubmed: 28663190
Invest Ophthalmol Vis Sci. 2021 Oct 4;62(13):20
pubmed: 34698774
N Engl J Med. 2012 Mar 29;366(13):1227-39
pubmed: 22455417
Int J Mol Sci. 2018 Nov 13;19(11):
pubmed: 30428543
Diabetes. 2016 Jan;65(1):172-87
pubmed: 26384381
Methods Mol Biol. 2012;933:291-302
pubmed: 22893415
Curr Diab Rep. 2006 Apr;6(2):102-7
pubmed: 16542619
Vision Res. 2004 Dec;44(28):3335-45
pubmed: 15536001
Br J Ophthalmol. 2012 Oct;96(10):1285-90
pubmed: 22887976
Eur J Ophthalmol. 2014 Mar-Apr;24(2):247-53
pubmed: 24030532
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):789-94
pubmed: 11222542
Sci Rep. 2020 Jan 14;10(1):206
pubmed: 31937811
J Neurosci Res. 2015 Jul;93(7):1079-92
pubmed: 25801286
Lancet. 2017 Jun 3;389(10085):2165-2166
pubmed: 28494921
Diabetologia. 2017 Nov;60(11):2285-2298
pubmed: 28779212
Diabetes. 2006 Sep;55(9):2401-11
pubmed: 16936187
Sci Rep. 2020 Feb 25;10(1):3375
pubmed: 32099056
Hum Mol Genet. 2018 Mar 1;27(5):761-779
pubmed: 29281027
J Clin Invest. 1996 Jun 15;97(12):2883-90
pubmed: 8675702
Circ J. 2015;79(5):934-41
pubmed: 25787231
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3800-6
pubmed: 16186366
J Vis Exp. 2017 Sep 22;(127):
pubmed: 28994761
J Vis Exp. 2013 Jun 13;(76):e50489
pubmed: 23793268
Clin Exp Ophthalmol. 2000 Feb;28(1):3-8
pubmed: 11345341
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2210-8
pubmed: 15914643
Mol Med. 1995 Jul;1(5):527-34
pubmed: 8529118
Clin Exp Optom. 2005 May;88(3):132-45
pubmed: 15926876